- FDA licenses Moderna's next generation mRNA COVID-19 Vaccine (mNexspike) for people age 12 to 64 years with high-risk conditions and all adults age 65 and older. ACIP will consider recommendations for its use at its June meeting.
- Immunize.org updates “Vaccine Administration Record for Children and Teens” and “Vaccine Administration Record for Adults”
- Immunize.org updates references in two more standing orders templates
- Immunize.org updates its "Notification of Immunization Letter Template"
- For National Men’s Health Week, June 9–15, encourage men to seek preventive care, including vaccination. Happy Father’s Day!
- Confirmed measles cases increase to 1,168 across 33 states; encourage vaccination
- Journalists interview Immunize.org experts
- Vaccines in the news
- Virtual: Register for Immunize.org Website Office Hours. Ask questions and learn about our "News & Updates" web section on June 11 at 4:00 p.m. (ET) or June 12 at 12:00 p.m. (ET). Recorded sessions archived.
- Virtual: AIM hosts webinar, “Responding to Measles Outbreaks in High Priority Populations Part II,” on June 17 at 2:00 p.m. (ET)
- Virtual: NFID hosts webinar, “Protecting Patients Before Travel,” on June 18 at 1:00 p.m. (ET); CE credit offered
- Virtual: Watch June 25–27 ACIP meeting with discussion of several vaccine recommendations, including COVID-19, HPV, influenza, meningococcal, and RSV
On May 30, FDA licensed mNexspike (Moderna) to prevent COVID-19 disease in adults age 65 years and older as well as those age 12 through 64 years with at least one underlying condition that elevates their risk for severe outcomes from COVID-19. Among other differences, a dose of mNexspike contains 10 mcg of messenger RNA, compared to 50 mcg in Moderna’s Spikevax messenger RNA vaccine.
At its June 25–27 meeting, ACIP will consider its recommendations for use of all available COVID-19 vaccines.
FDA posted the mNexspike package insert and approval letter.
Related Link
- Immunize.org: Vaccines A–Z: COVID-19 main page
Immunize.org updated vaccine administration records for children and teens and for adults, adding Penmenvy (MenABCWY, GSK), which was licensed on February 14, 2025. ACIP voted on recommendations for its use at the April meeting; these recommendations are pending acceptance by the CDC Director or Secretary of Health.
Related Links
- Immunize.org: Clinical Resources: Administering Vaccines main page
- Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria
Immunize.org continues to update its standing orders templates to remove the reference to the excipient table that used to appear in Appendix B of the Epidemiology and Prevention of Vaccine-Preventable Diseases (the "Pink Book"). The two updated standing order templates posted in the past week are:
- Standing Orders for Administering Meningococcal ACWY Vaccine to Children and Teens
- Standing Orders for Administering Meningococcal ACWY Vaccine to Adults
Previously announced updated standing orders templates include:
- Standing Orders for Administering Rotavirus Vaccine to Infants
- Standing Orders for Administering Human Papillomavirus Vaccine to Children and Teens (additional update to font and QR code)
- Standing Orders for Administering Human Papillomavirus Vaccine to Adults
- Standing Orders for Administering Hepatitis A Vaccine to Children and Teens
- Standing Orders for Administering Hepatitis A Vaccine to Adults
- Standing Orders for Administering Varicella Vaccine to Adults
- Standing Orders for Administering Varicella Vaccine to Children and Teens
- Standing Orders for Administering Haemophilus influenzae Type B Vaccine to Adults
- Standing Orders for Administering Pneumococcal Vaccines to Children and Teens
Related Links
- Immunize.org: Clinical Resources: Standing Orders Templates main page
- Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria
Immunize.org updated its Notification of Immunization Letter Template, adding Penmenvy (MenABCWY, GSK), which was licensed on February 14, 2025. ACIP voted on recommendations for its use at the April meeting; these recommendations are pending acceptance by the CDC Director or Secretary of Health.
Related Links
- Immunize.org: Clinical Resources: Documenting Vaccination main page
- Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria
For National Men’s Health Week, June 9–15, encourage men to seek preventive care, including vaccination. Happy Father’s Day!
National Men's Health Week is June 9–15, ending on Father's Day. This annual observance encourages men of all ages to prioritize their health and seek preventive care including recommended vaccines. Compared with women, men generally die earlier, become ill at a younger age, and develop more chronic illnesses, but are up to 50% less likely to seek medical care. According to CDC, more than 14% of adult men are in fair or poor health.
Encourage men to get up to date with vaccination. Men can learn what they may need in this easy-to-read version of CDC’s Recommended Immunizations for Adults. In addition to vaccines needed by age or health status, some may need additional vaccines based on their occupation. CDC resources on Traveler’s Health address vaccines needed for international travel. Also see Immunize.org's resource, Vaccinations for Men Who Have Sex with Men, for information about additional vaccines recommended for them, including mpox vaccine.
The HPV vaccine is critical cancer prevention for all young adults and teens, helping to prevent HPV-associated cancers of the mouth, throat, and genitals. Currently, about 16,000 HPV-associated cancers occur in men each year. All males age 9 through 26 years should be protected from HPV-related cancers through vaccination; men age 27 through 45 years should talk with their healthcare provider to decide if they would benefit.
Happy Father's Day to all the fathers among our IZ Express readers! Thank you for all you do to safeguard your family’s health. Remember to take care of your vaccination needs, too.
Related Links
- CDC: Men's Health main page
- CDC: Immunization Schedules main page
- Immunize.org: Vaccinations for Men Who Have Sex with Men (PDF)
As of June 5, CDC reported 1,168 confirmed measles cases in 2025 in 33 states, including the first case reported this year in South Dakota. This case occurred in an adult resident of Meade County who became ill after international travel. The states with the most confirmed cases in 2025 are Texas (742, 63.5%) and Kansas (71, 6.1%). Among confirmed cases, 12% were hospitalized and two out of three were younger than age 20 years.
CDC only requires reporting of laboratory-confirmed measles cases. Cases without laboratory testing for confirmation are not included in these numbers. Actual numbers of cases are, therefore, higher than confirmed case counts.
A map of 2025 measles cases in the contiguous United States, as of June 6, from the Johns Hopkins International Vaccine Access Center appears below. The U.S. Measles Tracker website includes state and county-level data.
CDC updated its Travelers' Health: Global Measles web page to encourage all international travelers to be fully vaccinated before travel. Additionally, CDC offers resources for communities experiencing a measles outbreak including infographics for families, images to help clinic personnel identify cases, guidance for caring for patients with measles, and a Be Ready for Measles communication toolkit. Spanish-language resources are now available on the toolkit page.
Related Links
- CDC: Measles Cases and Outbreaks main page
- CDC: Be Ready for Measles Toolkit
- Center for Outbreak Response Innovation: Measles Outbreak Response main page
- Immunize.org: Vaccines A–Z: Measles main page
- Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Children and Teens (PDF)
- Immunize.org: Standing Orders for Administering Measles, Mumps, and Rubella Vaccine to Adults (PDF)
- Immunize.org: Ask the Experts: MMR (Measles, Mumps, and Rubella) web page
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a recent citation.
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
- Washington Post: RFK Jr. Purges Every Vaccine Adviser on CDC Panel; Will Pick Replacements (6/9/25)
- New York Times: Whooping Cough Is Surging. Do You Need Another Shot? (6/6/25)
-
American Journal of Managed Care: ACP Experts Say FDA, CDC Moves May Undermine COVID-19 Vaccine Coverage for Millions (6/2/25)
- New York Times: Kennedy Says Healthy Kids Don’t Need COVID Shots. Is That True? (5/27/25)
This week, we continue highlighting our popular “Ask the Experts” section. This resource provides more than 1,300 practical answers to questions from healthcare professionals about vaccines and vaccine administration. Content is divided into two categories:
- Vaccine Topics—22 specific vaccines
- General Topics—10 vaccination-related categories
Larger topics feature subcategories to assist with your search.
Look at the left navigation menu. If there is a carat (>) next to the topic, click to expand the list of subcategories available. Clicking on a subcategory such as “Vaccine Recommendations” will filter results.
Browse the resulting questions or narrow your results with keyword search (marked 1 in the image above) or by choosing filters (2). Select the “Hide All Answers/Show All Answers” button (3) to hide or expand answer content. In the illustration above, “Hepatitis A,” followed by “Vaccine Recommendations,” and the keyword “Twinrix” produces two results.
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to the following helpful materials.
Immunize.org Updated Materials for Clinicians
Standing Orders Templates: see Top Story above for list.
- Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools
- Vaccine Storage Quick Reference
- Vaccine Storage Troubleshooting Record
- Vaccine History Timeline
- New! Website Office Hours: Publication Archives, Vaccine Timeline, & About Us
- New! Website Office Hours: Affiliated Websites
- Human Papillomavirus (HPV): Questions and Answers
- Human Papillomavirus (HPV): A Parent’s Guide to Preteen and Teen HPV Vaccination
- HPV Vaccine: A Guide for Adults Ages 18–26 Years
- Immunize.org: Clinical Resources: Screening Checklists main page
- Immunize.org: Clinical Resources A–Z main page to see educational materials sorted by category
- Immunize.org: Ask the Experts main page to access more than 1,200 questions answered by Immunize.org experts
Immunize.org recently updated its clinical resource titled Administering Vaccines: Dose, Route, Site, and Needle Size to add Penmenvy, the new MenABCWY vaccine from GSK.
IZ Express provides readers with information about new and updated VISs, translations, and resources. In April, Immunize.org provided updated Spanish translations (PDF and RTF for electronic medical record systems). In May, the Cerro Gordo County Public Health Department generously donated 16 new Pohnpeian VIS translations to post on the website.
The table below contains hyperlinks to the English vaccine VISs, 15 updated Spanish translations, and 16 new Pohnpeian translations.
Immunize.org offers three clinical resources that link to VISs via QR codes:
- QR Code Links to Routinely Recommended Vaccine Information Statements
- QR Code Links to All Vaccine Information Statements
- QR Code Links to Vaccine Information Statement (VIS) Translations: Influenza (Flu) Vaccine (Inactivated or Recombinant)
All these resources appear on our new Clinical Resources topic: VIS-Related Resources.
On May 29, CDC released updated VISs for pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV). Changes incorporate recommendations for the routine use of PCV for adults age 50 years and older (previously 65 years) and the limited use of PPSV23. The updated VISs refer to PCVs generally and no longer reference specific PCV products.
The use of the updated VISs should begin immediately. If you use Immunize.org’s QR code reference resources linking directly to the English VISs on our website, you can keep using them. These QR code documents automatically link to the updated VISs and ensure you are always accessing the current official version.
Immunize.org will create and post translations of these updated VISs in coming weeks. CDC notes that translated VISs that are out of date following publication of an updated version may continue to be used. The official English VIS must also be provided when providing any translation.
Laminated booklets of the 2025 U.S. adult immunization schedule are still available in the Immunize.org shop. The 2025 child and adolescent schedule booklets sold out.
The schedules are available online as PDFs from CDC at no cost. Immunize.org’s laminated booklets are ideal for use in any busy healthcare setting where vaccines are given.
Adult Booklets
1 copy: $10.00
2–4 copies: $9.50 each
5–19 copies: $8.50 each
20–99 copies: $7.50 each
100–499 copies: $6.00 each
500–999 copies: $5.00 each
1,000–1,999 copies: $4.00 each
2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules web page to view images and order today!
For additional information, call 651-647-9009 or email admininfo@immunize.org.
Related Links
- Immunize.org: Laminated Adult Immunization Schedules (19 and older) web page
- Immunize.org: Shop Immunize.org main page
Immunize.org offers a social media program to highlight our educational resources for a new audience of vaccinators. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Please view and share our newest feature, the Ask the Experts Video Series.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
- Facebook at ImmunizeOrg
- Instagram at ImmunizeOrg
- LinkedIn at Immunize.org
- YouTube at ImmunizeOrg
In the June 2 issue, JAMA published Trends in County-Level MMR Vaccination Coverage in Children in the United States. Parts of the research letter appear below.
Childhood vaccination has substantially reduced the incidence of vaccine-preventable diseases and saved countless children’s lives worldwide. The U.S. childhood vaccination program is estimated to have prevented more than 24 million cases of vaccine-preventable diseases in 2019 alone. Nonetheless, there is evidence of a U.S. national-level decline in the childhood measles-mumps-rubella (MMR) vaccination rate between 2019 and 2024. . . .
Our county-level dataset complements the state and national-level CDC data, confirming a widespread decline in MMR vaccination rates in the US after the COVID-19 pandemic while revealing significant heterogeneity in vaccination patterns within and across states. This dataset can be used in spatial and statistical analyses to identify factors associated with low or declining MMR rates in US counties and help inform targeted vaccination strategies to reduce the risk of measles outbreaks.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, June 11 at 4:00 p.m. (ET) or Thursday, June 12 at 12:00 p.m. (ET). The same content will be covered in both sessions.
We will open each 45-minute session with a short, live demonstration on navigating our News & Updates.
Register today for Immunize.org Website Office Hours (content is the same for both):
Th archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page. These archived programs include Ask the Experts; Clinical Resources; Vaccine Information Statements (VISs); Affiliated Websites; Images, Webinars, Videos, & Social Media; Official Guidance; Publication Archives, Vaccine Timeline, & About Us; Travel Vaccines, Vaccine Confidence, & Addressing Concerns; and Vaccines A–Z.
See our Calendar of Events for future Immunize.org Website Office Hours.
The Association of Immunization Managers (AIM) will present a 1-hour webinar titled Responding to Measles Outbreaks in High Priority Populations Part II beginning at 2:00 p.m. (ET) on June 17.
Based on feedback from Part I, this webinar will focus on strategies and engagement with close-knit communities.
Register for the webinar.
NFID will host a webinar titled Protecting Patients Before Travel at 1:00 p.m. (ET) on June 18. The panel includes NFID Medical Director Robert H. Hopkins Jr., MD; Chapman University School of Pharmacy Professor Jeffery A. Goad, PharmD, MPH; and ACIP member and Harvard Medical School Associate Professor Lin H. Chen, MD. Speakers will review current recommendations for travelers and share implementation strategies.
CME and CNE credit are available. There is no fee to participate in this activity, but preregistration is required.
Register for the webinar.
NFID hosts monthly webinars to increase awareness of the importance of infectious disease prevention and treatment. CME, CNE, and CPE credits are available for select recordings. View all archived NFID webinars.
CDC has been scheduled to convene the ACIP on June 25–27. Recommendation votes are scheduled for COVID-19, HPV, influenza, meningococcal, and RSV vaccines. Additionally, the agenda includes discussion of vaccines targeting anthrax, chikungunya, cytomegalovirus (CMV), Lyme, and pneumococcal diseases.
A recent HHS decision led to the dismissal of all 17 members of ACIP. HHS intends to replace those 17 members with new members currently under consideration and hold the June 25–27 meeting in Atlanta.
Related Links
- CDC: ACIP main page for access to webcast, agendas
- CDC: ACIP: Meeting Information for presentation slides, content from previous meetings, and information about future meetings
For more upcoming events, visit our Calendar of Events.